Autihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 1, 1998, Pages 79-86

  Guazzi, Maurizio D ^a,b   Campodonico, Jeness ^a   Celeste, Fabrizio ^a   Guazzi, Marco ^a   Santambrogio, Gloria ^a   Rossi, Marco ^a   Trabattoni, Daniela ^a   Alimento, Marina ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Istituto di Cardiologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NIFEDIPINE; ANTIHYPERTENSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; SODIUM RESTRICTION; SODIUM URINE LEVEL; SUPINE POSITION; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HOSPITALIZATION; MIDDLE AGED; NATRIURESIS;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD PRESSURE; DRUG ADMINISTRATION SCHEDULE; DRUG ANTAGONISM; DRUG THERAPY, COMBINATION; ENALAPRIL; HUMANS; HYPERTENSION; MIDDLE AGED; NATRIURESIS; SEVERITY OF ILLNESS INDEX;

EID: 0031594513     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90123-0     Document Type: Article

References (33)

1. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:1-80.
2. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
3. McGiff JC, Terragno NA, Malik KU, Lonigro AJ. Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circ Res 1972;31:36-43.
4. Blumberg AL, Denny SE, Marshall GR, Needleman P. Blood vessel-hormone interactions: angiotensin, bradykinin and prostaglandins. Am J Physiol 1977; 232:H305-10.
5. Moore TJ, Crantz FR, Hollenberg NK, Koletsky RJ, Leboff MS, Swartz SL, et al. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension 1981;3:168-73.
6. Quilley J, Duchin KL, Hudes EM, McGiff JC. The antihypertensive effect of captopril in essential hypertension: relationship to prostaglandins and the kallikrein-kinin system. J Hypertens 1987;5:121-8.
7. Cachofeiro V, Sakakibara T, Nasjletti A, Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 1992;19:138-45.
8. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20: 1549-55.
9. Zanzinger J, Zheng X, Bassenge E. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a brady-kinin dependent mechanism. Cardiovasc Res 1994;28: 209-14.
10. Guazzi M, Lauri GF, Melzi G, Cattadori G, Agostoni PG. Antagonismo di acido acetilsalicilico vs ACE-inibitore nell'insufficienza cardiaca congestizia rivelato da una diminuita capacità respiratoria e di esercizio. Cardiologia 1996;41:527-33.
11. Guazzi M, Marenzi GC, Alimento M, Contini M, Agostoni PG. Improvement of alveolar-capillary diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation 1997; 95:1930-6.
12. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
13. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987;32:1-12.
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.
15. The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992;327:685-91.
16. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 1992;340:1173-8.
17. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-31.
18. The Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation 1980;62:449-61.
19. Epstein M, Hollenberg NK. Age as a determinant of renal sodium conservation in normal man. J Lab Clin Med 1976;87:411-7.
20. Pickering G. High blood pressure. 2nd ed. New York: Grune and Stratton; 1968.
21. Hollenberg NK, Moore T, Shoback D, Redgrave J, Rabinowe S, Williams GH. Abnormal renal sodium handling in essential hypertension: relation to failure of renal and adrenal modulation of responses to angiotensin II. Am J Med 1986;81:412-8.
22. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-9.
23. Millar JA, McGrath BP, Matthews PG, Johnston CI. Acute effects of captopril on blood pressure and circulating hormone levels in salt-repleted and depleted normal subjects and essential hypertensive patients. Clin Sci 1981;61:75-83.
24. Goldstone R, Martin K, Zipser R, Horton R. Evidence for a dual action of converting enzyme inhibitor on blood pressure in normal man. Prostaglandins 1981;22:587-98.
25. Chalmers JP, West MJ, Wing LM, Bune AJ, Graham JR. Effects of indomethacin, sulindac, naproxen, aspirin and paracetamol in treated hypertensive patients. Clin Exp Hypertens 1984;A6:1077-93.
26. Vander AJ, Geelhoed GW. Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med 1965; 120:399-403.
27. Shade RE, David JO, Johnson JA, Gotshall RW, Spielman WS. Mechanism of action of angiotensin II and anti-diuretic hormone on renin secretion. Am J Physiol 1973;224:926-9.
28. Yun J, Kelly G, Bartter FC, Smith H Jr. Role of prostaglandins in the control of renin secretion in the dog. Circ Res 1977;40:459-64.
29. Bolger PM, Eisner GM, Ramwell PW, Slotkoff LM. Renal actions of prostaglandins. Nature 1978;271:467.
30. Wilson TW, Mc Cauley FA, Wells HD. Effects of low dose aspirin on responses to furosemide. J Clin Pharmacol 1986;26:100-5.
31. Imanishi M, Kawamura M, Akabane S, Matsushima Y, Kuramochi M, Ito K, et al. Aspirin lowers blood pressure in patients with renovascular hypertension. Hypertension 1989;14:461-8.
32. Doig JK, Lees KR, Reid JL. The effect of drags on the renin-angiotensin system in man. In: Robertson JI, Nicholls MG, editors. The renin-angiotensin system; vol 2 London: Gower Medical Publishing; 1993. p. 80.1-80.19.
33. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.